Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: A meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 14, 2015, Pages 4358-4364

  He, An Bing ^a   Peng, Xiu Lan ^a   Song, Jia ^b   Zhang, Ji Xing ^b   Dong, Wei Guo ^b,c   Luo, Ren Feng ^c   Tang, Yan ^a  

^a Fifth Hospital of Wuhan   (China)

^b JIANGHAN UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Capecitabine; Gastric cancer; Meta analysis; Randomized controlled trials; S 1

Indexed keywords

CAPECITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); HAND FOOT SYNDROME; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; HAND-FOOT SYNDROME; MORTALITY; ODDS RATIO; RISK FACTOR; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHI-SQUARE DISTRIBUTION; DRUG COMBINATIONS; HAND-FOOT SYNDROME; HUMANS; ODDS RATIO; OXONIC ACID; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927633179     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i14.4358     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
3. Wu HL, Tian Q, Peng CW, Liu SP, Li Y. Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pac J Cancer Prev 2011; 12: 3341-3345 [PMID: 22471477]
4. O'Connor KG. Gastric cancer. Semin Oncol Nurs 1999; 15: 26-35 [PMID: 10074655 DOI: 10.1016/S0749-2081(99)80037-0]
5. Kim YH. Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat 2005; 37: 79-86 [PMID: 19956484 DOI: 10.4143/crt.2005.37.2.79]
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909 [PMID: 16782930 DOI: 10.1200/JCO.2005.05.0245]
7. Hu JK, Li CM, Chen XZ, Chen ZX, Zhou ZG, Zhang B, Chen JP. The effectiveness of intravenous 5-fluorouracil-containing chemotherapy after curative resection for gastric carcinoma: A systematic review of published randomized controlled trials. J Chemother 2007; 19: 359-375 [PMID: 17855179 DOI: 10.1179/joc.2007.19.4.359]
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]
9. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-197 [PMID: 10765119 DOI: 10.1159/000012099]
10. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488-1497 [PMID: 15939717 DOI: 10.1093/annonc/mdi270]
11. Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, Ura T, Tajika M, Niwa Y, Muro K. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol 2013; 18: 539-546 [PMID: 22552360 DOI: 10.1007/s10147-012-0416-6]
12. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106 [PMID: 11689577]
13. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292 [PMID: 11304782]
14. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704 [PMID: 15987918 DOI: 10.1056/NEJMoa043116]
15. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012 [PMID: 18421053 DOI: 10.1200/JCO.2007.14.9898]
16. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19: 1720-1726 [PMID: 18550577 DOI: 10.1093/annonc/mdn370]
17. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
18. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289 DOI: 10.1056/NEJMoa072252]
19. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123 [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4]
20. Xiong HL, Liu XQ, Sun AH, He Y, Li J, Yuan X. Clinical comparison of Docetaxel combined with S-1 or Capecitabine in treating advanced gastric carcinoma. Xiandai Zhongliu Yixue 2013; 21: 581-584
21. Zhang ZD, Kong Y, MA F, Liu HX, Zhang B, Huang JX, Ma EM, Hua YW. Adjuvant chemotherapy with Oxaliplatin plus S-1 versus XELOX regimen for postoperative gastric cancer. Zhongguo Putong Waike Zazhi 2013; 22: 747-751
22. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99: 584-590 [PMID: 18665164 DOI: 10.1038/sj.bjc.6604536]
23. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012; 48: 518-526 [PMID: 22243774 DOI: 10.1016/j.ejca.2011.12.017]
24. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168: 597-608 [PMID: 12699095 DOI: 10.1080/11024150201680005]
25. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother 2006; 18: 311-317 [PMID: 17129844]
26. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
27. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673 [PMID: 19153121 DOI: 10.1093/annonc/mdn717]
28. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 2007; 12: 543-554 [PMID: 17522242]
29. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003; 6 Suppl 1: 2-8 [PMID: 12775012]
30. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-1720 [PMID: 9893658]
31. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553 [PMID: 20159816 DOI: 10.1200/JCO.2009.25.4706]
32. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY. A phase II trial of capecitabine in previously untreated patients with advanced and/ormetastatic gastric cancer. Ann Oncol 2004; 15: 1344-1347 [PMID: 15319239]
33. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabineand oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46 [PMID: 18172173 DOI: 10.1056/NEJMoa073149]
34. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281 [PMID: 9849491]
35. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98 [PMID: 11784875]